CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation

Chin Med J (Engl). 2022 Jan 5;135(1):98-100. doi: 10.1097/CM9.0000000000001491.

Authors

Qianwen Xu¹, Hui Xu², Lei Xue², Min Wang³, Guiwang Pan³, Xuhan Zhang², Kaidi Song², Wen Yao², Xiang Wan², Juan Tong², Huilan Liu², Hanying Xu³, Xin Liu², Xiaoyu Zhu², Zimin Sun², Lin Yang³, Xingbing Wang^{1

2}

Affiliations

¹ Department of Hematology, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230031, China.
² Department of Hematology, The First Affiliated Hospital of USCT, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China.
³ PersonGen-Anke Cellular Therapeutics Co., Ltd., Hefei, Anhui 230001, China.

No abstract available

Publication types

Letter

MeSH terms

Antigens, CD19
Cord Blood Stem Cell Transplantation*
Humans
Immunotherapy, Adoptive
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen*
T-Lymphocytes

Substances

Antigens, CD19
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen